PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 35/00, 48/00, C12N 15/11, 15/85 — A1

(11) International Publication Number: **WO 00/10578**

(43) International Publication Date: 2 March 2000 (02.03.00)

(21) International Application Number: PCT/US99/19416

(22) International Filing Date: 25 August 1999 (25.08.99)

(30) Priority Data:
09/148,547 25 August 1998 (25.08.98) US

(71) Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).

(72) Inventor: SEMENZA, Gregg, L.; 718 Scarlett Drive, Towson, MD 21286 (US).

(74) Agent: HAILE, Lisa, A.; Gray Cary Friedenrich & Ware LLP, Suite 1600, 4365 Executive Square, San Diego, CA 92121-2189 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims.

(54) Title: STABLE HYPOXIA INDUCIBLE FACTOR-1 alpha AND METHOD OF USE

(57) Abstract

Substantially purified stable human hypoxia-inducible factor-1α (sHIF-1alpha) proteins and polynucleotides encoding stable human hypoxia-inducible factor-1α proteins are provided. A method is provided for treating a hypoxia-related tissue damage in a subject by administering to the subject a therapeutically effective amount of an sHIF-1alpha protein or a nucleic acid encoding a stable HIF-1alpha protein. Formulations are provided for the administration of stable human hypoxia inducible factor-1α (HIF-1alpha) polypeptide or a polynucleotide encoding stable human hypoxia inducible factor-1alpha (HIF-1alpha) to a patient having or at risk of having hypoxia- or ischemia-related tissue damage.